Recent Analysts' Ratings Changes for Trinity Biotech


4/13/2018 - Trinity Biotech was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating. According to Zacks, "Trinity Biotech plc, headquartered in Bray, the Republic of Ireland, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care segments of the diagnostic market worldwide.



from Biotech News